Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: Interaction with the effects of adenosine A2A antagonism

European Journal of Neuroscience

Volumn 38, Issue 1, 2013, Pages 2183-2191

  Collins Praino, Lyndsey E ^a,d   Paul, Nicholas E ^a   Ledgard, Felicia ^b   Podurgiel, Samantha J ^a   Kovner, Rotem ^a   Baqi, Younis ^c   Müller, Christa E ^c   Senatus, Patrick B ^b   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

acetylcholine; dopamine; muscarinic; Parkinson's disease; tremulous jaw movements

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; MSX 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN REGION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NONHUMAN; PARKINSONISM; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS; TREATMENT RESPONSE; TREMOR;

ACETYLCHOLINE; DOPAMINE; MUSCARINIC; PARKINSON'S DISEASE; TREMULOUS JAW MOVEMENTS;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; DEEP BRAIN STIMULATION; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; GALANTAMINE; JAW; MALE; MOVEMENT; PARKINSON DISEASE, SECONDARY; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; SUBTHALAMIC NUCLEUS; TREMOR; XANTHINES;

EID: 84879844751     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12212     Document Type: Article

References (83)

1. Aarsland, D., Hutchinson, M. & Larsen, J.P. (2003) Cognitive, psychiatric, and motor response to galantamine in Parkinson's disease with dementia. Int. J. Geriatr. Psych., 18, 937-941.
2. Akita, H., Honda, Y., Ogata, M., Noda, K. & Saji, M. (2010) Activation of the NMDA receptor involved in the alleviating after-effect of repeated stimulation of the subthalamic nucleus on motor deficits in hemiparkinsonian rats. Brain Res., 1306, 159-167.
3. Ashkan, K., Wallace, B., Bell, B.A. & Benabid, A.L. (2004) Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on? Brit. J. Neurosurg., 18, 19-34.
4. Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M.J., Mouradian, M.M. & Chase, T.N. (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology, 61, 293-296.
5. Baunez, C. (2011) A few examples of the contribution of animal research in rodents for clinical application of deep brain stimulation. Prog. Brain Res., 194, 105-116.
6. Bejjani, B.P., Gervais, D., Arnulf, I., Papadopoulos, S., Demeret, S., Bonnet, A.M., Cornu, P., Damier, P. & Agid, Y. (2000) Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J. Neurol. Neurosur. Ps., 68, 595-600.
7. Bergman, H. & Deuschl, G. (2002) Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Movement Disord., 17(suppl. 3), s28-s40.
8. Betz, A.J., McLaughlin, P.J., Burgos, M., Weber, S.M. & Salamone, J.D. (2007) The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology, 194, 347-359.
9. 2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience, 163, 97-108.
10. Beurrier, C., Biolac, B., Audin, J. & Hammond, C. (2001) High-frequency stimulation produces a transient blockade of voltage-gated currents in subthalamic neurons. J. Neurophysiol., 85, 1351-1356.
11. Brown, A.R., Antle, M.C., Hu, B. & Teskey, G.C. (2011) High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats. Exp. Neurol., 231, 82-90.
12. Brown, P. & Eusebio, A. (2008) Paradoxes of functional neurosurgery: clues from basal ganglia recordings. Movement Disord., 23, 12-20.
13. Clarimon, J., Pagonabarraga, J., Paisan-Ruiz, C., Campolongo, A., Pascual-Sedano, B., Marti-Masso, J.F., Singleton, A.B. & Kulisevsky, J. (2008) Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. Movement Disord., 15, 518-523.
14. 1 antagonist DPCPX: possible relevance for drug-induced parkinsonism. Pharmacol. Biochem. Be., 94, 561-569.
15. Collins, L.E., Galtieri, D.J., Collins, P., Jones, S.K., Port, R.G., Paul, N.E., Hockemeyer, J., Müller, C.E. & Salamone, J.D. (2010b) Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity. Behav. Brain Res., 211, 148-155.
16. Collins, L.E., Paul, N.E., Abbas, S.F., Leser, C.E., Galtieri, D.J., Chrobak, J.J., Baqi, Y., Müller, C.E. & Salamone, J.D. (2011) Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. Pharmacol. Biochem. Be., 99, 414-422.
17. Collins-Praino, L.E., Paul, N.E., Rychalsky, K.L., Hinman, J.R., Chrobak, J.J., Senatus, P.B. & Salamone, J.D. (2011) Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Front. Syst. Neurosci., 5, 49.
18. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav. Brain Res., 148, 47-54.
19. Cousins, M.S., Carriero, D.L. & Salamone, J.D. (1997) Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur. J. Pharmacol., 322, 137-145.
20. Creed, M., Hamani, C. & Nobrega, J.N. (2011) Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Eur. Neuropsychopharm., 21, 393-400.
21. Cunha, G.M., Canasm, P.M., Melo, C.S., Hockemeyer, J., Muller, C.E., Oliveira, C.R. & Cunha, R.A. (2008) Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp. Neurol., 210, 776-781.
22. Dall'igna, O.P., Fett, P., Gomes, M.W., Souza, D.O., Cunha, R.A. & Lara, D.R. (2007) Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol., 203, 241-245.
23. Daniels, C., Krack, P., Volkmann, J., Pinsker, M.O., Krause, M., Tronnier, V., Kloss, M., Schnitzler, A., Wojtecki, L., Botzel, K., Danek, A., Hilker, R., Sturm, V., Kupsch, A., Karner, E., Deuschl, G. & Witt, K. (2010) Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Movement Disord., 25, 1583-1589.
24. Darbaky, Y., Forni, C., Amalric, M. & Baunez, C. (2003) High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor function in rats, but less efficiency in a choice reaction time task. Eur. J. Neurosci., 18, 951-956.
25. Deuschl, G., Raethjen, J., Baron, R., Lindemann, M., Wilms, H. & Krack, P. (2000) The pathophysiology of parkinsonian tremor: a review. J. Neurol., 247(Suppl.5), V/33-V/956.
26. Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., Gruber, D., Hamel, W., Herzog, J., Hilker, R., Klebe, S., Kloss, M., Koy, J., Krause, M., Kupsch, A., Lorenz, D., Lorenzl, S., Mehdorn, H.M., Moringlane, J.R., Oertel, W., Pinsker, M.O., Reichmann, H., Reuss, A., Schneider, G.H., Schnitzler, A., Steude, U., Sturm, V., Timmermann, L., Tronnier, V., Trottenberg, T., Wojtecki, L., Wolf, E., Poewe, W. & Voges, J. (for the German Parkinson Study Group, Neurostimulation Section). (2006) A randomized trial of deep-brain stimulation for Parkinson's disease. New Engl. J. Med., 355, 896-908.
27. Drago, A., Crisafulli, C. & Serretti, A. (2011) The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am. J. Med. Genet. B., 156B, 975-986.
28. Factor, S., Mark, M.H., Watts, R., Struck, L., Mori, A., Ballerini, R., Sussman, N.M. & Istradefylline 6002-US-007 Study Group (2010) A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat. D., 16, 423-426.
29. Fang, X., Sugiyama, K., Akamine, S., Sun, W. & Namba, H. (2010) The different performance among motor tasks during the increasing current intensity of deep brain stimulation of the subthalamic nucleus in rats with different degrees of unilateral striatal lesion. Neurosci. Lett., 480, 64-68.
30. Farrar, A.M., Segovia, K.N., Randall, P.A., Nunes, E.J., Collins, L.E., Stopper, C.M., Port, R.G., Hockemeyer, J., Müller, C.E., Correa, M. & Salamone, J.D. (2010) Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and (DA) D2 receptors. Neuroscience, 166, 1056-1067.
31. Ferré, S., Popoli, P., Gimenez-Llort, L., Rimondini, R., Müller, C.E., Stromberg, I., Ogren, O. & Fuxe, K. (2001) Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. D., 7, 235-241.
32. Ferré, S., Ciruela, F., Canals, M., Marcellino, D., Burgueno, J., Casado, V., Hillion, J., Torvinen, M., Fanelli, F., Benedetti, P.P., Goldberg, S.R., Bouvier, M., Fuxe, K., Agnati, L.F., Lluis, C., Franco, R. & Woods, A. (2004) Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. D., 10, 265-271.
33. Ferré, S., Quiroz, C., Woods, A.S., Cunha, R., Popoli, P., Ciruela, F., Lluis, C., Franco, R., Azdad, K. & Schiffmann, S.N. (2008) An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Design, 14, 1468-1474.
34. Fink, J.S., Weaver, D.R., Rivkees, S.A., Peterfreund, R.A., Pollack, A.E., Adler, E.M. & Reppert, S.M. (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res., 14, 186-195.
35. Funkiewiez, A., Ardouin, C., Caputo, E., Krack, P., Fraix, V., Klinger, H., Chabardes, S., Foote, K., Benabid, A.L. & Pollak, P. (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behavior in Parkinson's disease. J. Neurol. Neurosur. Ps., 75, 834-839.
36. Fuxe, K., Ferré, S., Genedani, S., Franco, R. & Agnati, L.F. (2007) Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav., 92, 210-217.
37. Garcia, L., D'Alessandro, G., Bioulac, B. & Hammond, C. (2005) High-frequency stimulation in Parkinson's disease: more or less? Trends Neurosci., 28, 209-216.
38. Grace, J., Amick, M.M. & Friedman, J.H. (2009) A double blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J. Neurol. Neurosur. Ps., 80, 18-23.
39. Higginson, C.I., Wheelock, V.L., Levine, D., King, D.S., Pappas, C.T. & Sigvardt, K.A. (2009) The clinical significance of neuropsychological changes following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. J. Clin. Exp. Neuropsyc., 31, 65-72.
40. Hockemeyer, J., Burbiel, J.C. & Müller, C.E. (2004) Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J. Org. Chem., 69, 3308-3318.
41. Hoehn, M.M. & Yahr, M.D. (2001) Parkinsonism: onset, progression, and mortality 1967. Neurology, 57(10 Suppl 3), S22-S26.
42. Ishiwari, K., Betz, A., Weber, S., Felsted, J. & Salamone, J.D. (2005) Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacol. Biochem. Be., 80, 351-362.
43. Jenner, P. (2005) Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Inv. Drug., 14, 729-738.
44. Jicha, G.A. & Salamone, J.D. (1991) Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms. J. Neurosci., 11, 3822-3829.
45. Krack, P., Batir, A., Van Biercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P.D., Benazzouz, A., LeBas, J.F., Benabid, A.L. & Pollak, P. (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. New Engl. J. Med., 349, 1925-1934.
46. Levy, R., Hutchison, W.D., Lozano, A.M. & Dostrovsky, J.O. (2000) High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor. J. Neurosci., 20, 7766-7775.
47. LeWitt, P.A., Guttman, M., Tetrud, J.W., Tuite, P.J., Mori, A., Chaikin, P. & Sussman, N.M. (2008) 6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol., 63, 295-302.
48. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Broussolle, E., Perret, J.E. & Benabid, A.L. (1995) Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Movement Disord., 10, 672-674.
49. Litvinenko, I.V., Odinak, M.M., Mogil'naya, V.I. & Emelin, A.Y. (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci. Behav. Physiol., 38, 937-945.
50. Mansur, P.H.G., Cury, L.K.P., Andrade, A.O., Pereira, A.A., Miotto, G.A., Soares, A.B. & Naves, E.L. (2007) A review of techniques for tremor recording and quantification. Crit. Rev. Biomed. Eng., 35, 343-362.
51. Marsden, C., Duvoisin, R., Jenner, P., Parkes, J., Pycock, C. & Tarsy, D. (1975) Relationship between animal models and clinical parkinsonism. Adv. Neurol., 9, 165-175.
52. Miller, W.C. & DeLong, M.R. (1987) Altered tonic activity of neurons in the globus palidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In Carpenter, M.B. & Jayaraman, A. (Eds), The Basal Ganglia II. Plenum Press, New York, pp. 415-427.
53. Miwa, H., Koh, J., Kajimoto, Y. & Kondo, T. (2011) Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacol. Biochem. Be., 97, 656-659.
54. Morelli, M. & Pinna, A. (2002) Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol. Sci., 22, 71-72.
55. Morelli, M., Di Paolo, T., Wardas, J., Calon, F., Xiao, D. & Schwarzschild, M.A. (2007) Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol., 83, 293-309.
56. Moro, E., Esselink, R.J., Xie, J., Hommel, M., Benabid, A.L. & Pollak, P. (2002) The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology, 59, 706-713.
57. Moro, E., Lozano, A.M., Pollak, P., Agid, Y., Rehncrona, S., Volkmann, J., Kulisevsky, J., Obeso, J.A., Albanese, A., Hariz, M.I., Quinn, N.P., Speelman, J.D., Benabid, A.L., Fraix, V., Mendes, A., Welter, M.L., Houeto, J.L., Cornu, P., Dormont, D., Tornqvist, A.L., Ekberg, R., Schnitzler, A., Timmermann, L., Wojtecki, L., Gironell, A., Rodriguez-Oroz, M.C., Guridi, J., Bentivoglio, A.R., Contarino, M.F., Romito, L., Scerrati, M., Janssens, M. & Lang, A.E. (2010) Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Movement Disord., 25, 578-586.
58. Paxinos, G. & Watson, C. (2006) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
59. Perlmutter, J.S. & Mink, J.W. (2006) Deep brain stimulation. Annu. Rev. Neurosci., 29, 229-257.
60. Pinna, A. (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin. Inv. Drug., 18, 1619-1631.
61. Pinna, A., Wardas, J., Simola, N. & Morelli, M. (2005) New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci., 77, 3259-3267.
62. Pinna, A., Schintu, N., Simola, N., Volpini, R., Pontis, S., Cristalli, G. & Morelli, M. (2010) A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology, 58, 613-623.
63. Rathbone, J. & McMonagle, T. (2007) Pimozide for schizophrenia or related psychoses. Cochrane Db. Syst. Rev., 3, CD001949.
64. Rinehardt, E., Duff, K., Schoenberg, M., Mattingly, M., Bharucha, K. & Scott, J. (2010) Cognitive change on the repeatable battery of neuropsychological status (RBANS) in parkinson's disease with and without bilateral subthalamic nucleus deep brain stimulation surgery. Clin. Neuropsychol., 24, 1339-1354.
65. Rosin, D.L., Robeva, A., Woodard, R.L., Guyenet, P.G. & Linden, J. (1998) Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol., 401, 163-186.
66. Salamone, J.D., Mayorga, A.J., Trevitt, J.T., Cousins, M.S., Conlan, A. & Nawab, A. (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol., 56, 591-611.
67. Salamone, J.D., Carlson, B.B., Rios, C., Lentini, E., Correa, M., Wisniecki, A. & Betz, A. (2005) Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav. Brain Res., 156, 173-179.
68. Salamone, J.D., Betz, A.J., Ishiwari, K., Felsted, J., Madson, L., Mirante, B., Clark, K., Font, L., Korbey, S., Sager, T.N., Hockemeyer, J. & Müller, C.E. (2008a) Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front. Biosci., 13, 3594-3605.
69. Salamone, J.D., Ishiwari, K., Betz, A.J., Farrar, A.M., Mingote, S.M., Font, L., Hockemeyer, J., Müller, C.E. & Correa, M. (2008b) Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat. D., 14, S130-S134.
70. Salamone, J.D., Correa, M., Farrar, A.M., Nunes, E.J. & Collins, L.E. (2010) The role of dopamine/adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation. Future Neurology, 5, 377-392.
71. Santerre, J.L., Nunes, E.J., Randall, P.A., Baqi, Y., Müller, C.E. & Salamone, J.D. (2012) Behavioral studies with the novel adenosine A2A antagonist MSX-4: reversal of the effects of dopamine D2 antagonism. Pharmacol. Biochem. Be., 102, 477-487.
72. Schwarzschild, M.A., Agnati, L., Fuxe, K., Chen, J.F. & Morelli, M. (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci., 29, 647-654.
73. Shen, H.Y. & Chen, J.F. (2009) Adenosine A2A receptors in psychopharmacology: modulators of behavior, mood, and cognition. Curr. Neuropharmacol., 7, 195-206.
74. Simola, N., Fenu, S., Baraldi, P.G., Tabrizi, M.A. & Morelli, M. (2004) Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp. Neurol., 189, 182-188.
75. Spieles-Engermann, A.L., Collier, T.J. & Sortwell, C.E. (2010) A functionally relevant and long-term model of deep brain stimulation of the rat subthalamic nucleus: advantages and considerations. Eur. J. Neurosci., 32, 1092-1099.
76. Stacy, M., Silver, D., Mendis, T., Sutton, J., Mori, A., Chaikin, P. & Sussman, N.M. (2008) A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology, 70, 2233-2240.
77. Sultana, A. & McMonagle, T. (2000) Pimozide for schizophrenia and related psychoses. Cochrane Db. Syst. Rev., 3, CD001949.
78. Svenningsson, P., Le Moine, C., Fisone, G. & Fredholm, B.B. (1999) Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol., 59, 355-396.
79. Takahashi, R.N., Pamplona, F.A. & Prediger, R.D. (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front. Biosci., 13, 2614-2632.
80. Tronci, E., Simola, N., Borsini, F., Schintu, N., Frau, L., Carminati, P. & Morelli, M. (2007) Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur. J. Pharmacol., 566, 94-102.
81. Wang, J.H., Ma, Y.Y. & van den Buuse, M. (2006) Improved spatial recognition memory in mice lacking adenosine A2A receptors. Exp. Neurol., 199, 438-445.
82. Wei, C.J., Li, W. & Chen, J.F. (2011) Normal and abnormal functions of adenosine receptors in the central nervous system as revealed by genetic knockout studies. Biochim. Biophys. Acta, 1808, 1358-1379.
83. Windels, F., Bruet, N., Poupard, A., Feuerstein, C., Betrand, A. & Savasta, M. (2003) Influence of the frequency parapeter on extracellular glutamate and γ-aminobutyric acid in substantia nigra and globus pallidus during electrical stimulation of subthalamic nucleus in rats. J. Neurosci. Res., 72, 259-267.